

APPENDIX

Supplementary Table I. Linkage to care by halfway houses.

Group	No.		%	No. linked/HCV cases (%)		
	HCV positive	Screened		HCV seroprevalence	Linkage to specialist care, RNA confirmation	Treatment discussion
Standard access						
1	3	8	37.5	1/3 (33.3)	0/3 (0.0)	0/3 (0)
2	2	15	13.3	1/2 (50.0)	1/2 (50.0)	1/2 (50.0)
3	21	59	35.6	6/21 (28.6)	1/21 (4.8)	0/21 (0)
4	7	26	26.9	3/7 (42.9)	1/6* (16.7)	0/6* (0)
5	10	25	40.0	2/10 (20.0)	0/10 (0)	0/10 (0)
6	10	22	45.5	9/10 (60.0)	3/9* (33.3)	0/9* (0)
7	3	10	30.0	0/3 (0)	0/3 (0)	0/3 (0)
8	4	7	57.1	1/4 (25.0)	1/4 (25.0)	1/4 (25.0)
9	9	16	56.3	5/9 (55.6)	5/9 (55.6)	2/9 (22.2)
Total	69	188	36.7	28/69 (40.6)	12/67 (17.9)	4/67 (6.0)
Direct access						
1	10	33	30.3	3/10 (30.0)	1/10 (10.0)	1/10 (10.0)
2	4	12	33.3	2/4 (50.0)	1/3* (33.3)	1/3 (33.3)
3	4	24	16.7	4/4 (100.0)	2/3* (66.7)	2/3 (66.7)
4	8	52	15.4	6/8 (75.0)	5/8 (62.5)	5/8 (62.5)
5	12	42	28.6	9/12 (75.0)	6/12 (50.0)	0/12 (0)
Total	38	163	23.3	24/38 (63.2)	15/36 (41.7)	9/36 (25.0)
Overall	107	351	30.5	52/107 (48.6)	27/103 (26.2)	13/103 (12.6)

*Two patients from each group were HCV RNA negative and excluded from subsequent linkage to care analysis. HCV: hepatitis C virus